A detailed history of New Edge Advisors, LLC transactions in Beyond Air, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 73,098 shares of XAIR stock, worth $29,239. This represents 0.0% of its overall portfolio holdings.

Number of Shares
73,098
Previous 75,107 2.67%
Holding current value
$29,239
Previous $40,000 30.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.36 - $0.64 $723 - $1,285
-2,009 Reduced 2.67%
73,098 $28,000
Q2 2024

Aug 15, 2024

SELL
$0.54 - $1.67 $1,152 - $3,565
-2,135 Reduced 2.76%
75,107 $40,000
Q1 2024

May 14, 2024

SELL
$1.3 - $2.15 $729 - $1,206
-561 Reduced 0.72%
77,242 $134,000
Q4 2023

Feb 13, 2024

SELL
$1.4 - $2.46 $152 - $268
-109 Reduced 0.14%
77,803 $152,000
Q3 2023

Nov 14, 2023

SELL
$2.31 - $4.18 $753 - $1,362
-326 Reduced 0.42%
77,912 $179,000
Q2 2023

Aug 14, 2023

SELL
$4.26 - $6.92 $5,866 - $9,528
-1,377 Reduced 1.73%
78,238 $333,000
Q1 2023

May 12, 2023

SELL
$5.65 - $7.56 $10,170 - $13,608
-1,800 Reduced 2.21%
79,615 $537,000
Q4 2022

Feb 14, 2023

SELL
$5.47 - $7.9 $17,389 - $25,114
-3,179 Reduced 3.76%
81,415 $528,000
Q3 2022

Nov 14, 2022

BUY
$7.42 - $11.39 $19,885 - $30,525
2,680 Added 3.27%
84,594 $629,000
Q2 2022

Aug 09, 2022

SELL
$4.96 - $7.83 $10,778 - $17,014
-2,173 Reduced 2.58%
81,914 $548,000
Q1 2022

May 13, 2022

SELL
$6.33 - $9.53 $25,788 - $38,825
-4,074 Reduced 4.62%
84,087 $562,000
Q4 2021

Feb 17, 2022

SELL
$8.44 - $15.61 $402,613 - $744,643
-47,703 Reduced 35.11%
88,161 $832,000
Q3 2021

Oct 29, 2021

SELL
$5.9 - $12.54 $477 - $1,015
-81 Reduced 0.06%
135,864 $1.51 Million
Q2 2021

Jul 22, 2021

BUY
$4.72 - $7.15 $641,660 - $972,006
135,945 New
135,945 $881,000

Others Institutions Holding XAIR

About Beyond Air, Inc.


  • Ticker XAIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 29,888,000
  • Market Cap $12M
  • Description
  • Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment ...
More about XAIR
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.